XBiotech Inc. (NASDAQ:XBIT) was down 6% on Monday . The stock traded as low as $14.27 and last traded at $14.50, with a volume of 170,470 shares. The stock had previously closed at $15.42.

Several equities research analysts recently weighed in on XBIT shares. Noble Financial reaffirmed a “buy” rating and set a $30.00 target price (up from $24.00) on shares of XBiotech in a research note on Tuesday, June 28th. Zacks Investment Research raised shares of XBiotech from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Tuesday, May 24th.

The firm’s market cap is $492.79 million. The firm has a 50 day moving average of $15.99 and a 200 day moving average of $12.84.

In other news, Director W Thorpe Mckenzie purchased 20,000 shares of the stock in a transaction dated Thursday, May 26th. The stock was acquired at an average cost of $13.96 per share, for a total transaction of $279,200.00. Following the completion of the acquisition, the director now directly owns 3,898,600 shares in the company, valued at approximately $54,424,456. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.